Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of SA 14-14-2 JE Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Infant's parent(s) or legal guardian(s) willing to provide signed informed consent.~* Healthy infants aged 10 to 12 months at enrollment residing in Matlab HDSS intervention area who have completed all doses of EPI immunizations (BCG, DPT, HBV, Hib, OPV and measles) at least 4 weeks prior to enrollment.~Exclusion Criteria:~* Acute medical illness with or without fever within the last 72 hours or an axillary temperature (≥ 37.5°C ) at the time of vaccination.~* Use of antibiotics or antipyretics within the last 72 hours prior to enrollment.~* Severely or moderately malnourished infants (\<-3 Z score).~* History of prematurity (\< 36 weeks of pregnancy).~* Underlying medical condition such as failure to thrive, inborn errors of metabolism, bronchopulmonary dysplasia, or any major congenital abnormalities requiring surgery or chronic treatment.~* History of serious chronic disease (e.g., cardiac, renal, neurologic, metabolic, rheumatologic, hematologic, or bleeding disorder).~* Known or suspected impairment of immunologic function.~* History of documented or suspected encephalitis or meningitis.~* History of seizures, including history of febrile seizures, or any other neurologic disorder.~* History of JE infection.~* Prior receipt of a JE vaccine.~* Received measles vaccine within 4 weeks prior to, or scheduled to receive a vaccination during, the conduct of this trial.~* Prior or anticipated receipt of immune globulin or other blood products, or injected or oral corticosteroids or other immune modulator therapy within 6 weeks of administration of the study vaccine.~* Serious adverse reactions (e.g. urticaria, angioedema, shock, breathlessness following vaccination or any life threatening condition) with any previous EPI vaccine.~* Unable to attend the scheduled visits or comply with the study procedures.~* Enrolled in another clinical trial involving any therapy.~* Any condition that in the opinion of the investigator, would pose a health risk to the child, or interfere with the evaluation of the study objectives.

- Gender: ALL
- Minimum Age: 10 Months
- Maximum Age: 12 Months
- Healthy Volunteers: t

Study Arms:
- JE Vaccine existing facilities (Type: ACTIVE_COMPARATOR): will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
- JE vaccine new plant lot 1 (Type: ACTIVE_COMPARATOR): Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
- JE vaccine new plant lot 2 (Type: ACTIVE_COMPARATOR): Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
- JE vaccine new plant lot 3 (Type: ACTIVE_COMPARATOR): Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete